Meet the woman who's taking the pharmaceutical world by storm. With her unparalleled expertise in strategy and forecasting, she's become a sought-after member of advisory boards for top conferences and juries. Her insights are highly valued at events such as the Pharmaceutical Market Research Conference USA, CPHI Barcelona, and Medtech Intelligence trade magazine. And when it comes to speaking engagements, she's a regular on the circuit, delivering keynote addresses at prestigious events around the world. In April 2023, her tireless efforts and outstanding leadership were recognized when she was named one of the "Top 50 Inspiring Women" and received the "Changemaker for the Year" award from Medgate.

Sanobar Syed
Sanobar Syed Sanobar Syed

Sanobar Syed is a seasoned business leader in establishing and leading pharmaceutical strategy and forecasting with top pharmaceutical global giants like Beigene, AbbVie, Novartis, McKesson to name a few. She is a trailblazer in global launch excellence forecasting, strategic insight generation, and business strategy and planning. In her career over 14+ years she has ensured strong alignment with cross-functional teams and provides strategic support to critical activities like global brand launches, valuation of potential in licensing and business development opportunities, earnings prep documents, and investor relation call events which have helped drive forward looking critical decisions for the companies.

Syed has successfully managed short and long-range strategic forecast assumptions across difficult therapy areas like oncology & rare diseases, neurosciences, in the pharmaceutical industry. She collaborates with global brand leaders to strategize and optimise forecast design, patient flow, and share patient and epidemiology models. Her work impacts across cross functional teams like Supply chain, Finance, Product planning, market access and marketing, and overall organizational levelHer in-depth understanding of qualitative and quantitative research methods has allowed her to incorporate outcomes into robust forecasting deliverables. With the advent of technology and the increased adoption of AI and predictive tools in pharma she is a champion and advocate to use it to drive favorable patient outcomes in the pharmaceutical world.

Sanobar Syed has held leadership positions in the pharmaceutical industry. She is a sub-board executive for Women Leaders in Pharma, an ex-strategy co-chair at AbbVie Women Leaders in Action's global committee, key member of IDEA council at Beigene and a multiple-time mentor at the Toronto Region of Immigrant Council and Access Employment. She has also been a guest speaker at global conferences on business strategy, forecasting & business excellence, including Reuters, Schulich Healthcare and Biotechnology Forum, and developed curriculum at Toronto Metropolitan University in Canada.

Syed's core business skills include cross-functional team and people management, sales and marketing, market access, demand and supply functions, financial modelling, analytics and forecasting, , customer intelligence and market insights, due diligence, as well as change management. Her influence without authority has been one of the most sought-after traits among her peers and colleagues.

Currently, Syed serves as the market insights and strategy lead at BeiGene, , where she actively influenced commercial forecasting strategy and global launch planning efforts for Brukinsa, BeiGene's first product launch in Europe and Canada. She created a "one source of truth" forecast and buy-in across finance, supply chain, sales and marketing teams. which are critical roles to succeed in any key pharmaceutical launch.

Before joining BeiGene, Syed was the Canada lead manager for forecasting and strategy at AbbVie. She created and delivered forecasts for key brand portfolios and led forecasting and strategic planning for business unit directors. Her portfolio included over 13 brands, accounting for over 300 million Canadian dollars yearly across key brands like Botox, Coolscultping, Vraylar, Atogepant and Ubrogepant. She planned and implemented complex cross-functional initiatives, such as leading forecasting workstreams in the integration of the AbbVie-Allergan acquisition. After the AbbVie-Allergan merger, she successfully integrated priority Legacy Allergan brands in 6 months. Syed has hands-on experience with qualitative and quantitative research methods and has advised leadership in all aspects of operational knowledge, R&D, drug licensing, partnerships and management projects. She has driven brand launch initiatives and projects at Dr. Reddys, Aurobindo Pharma and Biocon.

In conclusion, Syed's experience and expertise in the pharma industry make her a valuable asset to any company. Her ability to drive brand launch initiatives and projects, as well as her hands-on experience with research methods and advising leadership, demonstrate her leadership and strategic foresight. Syed's track record of success speaks for itself and makes her a leader in the industry.